| answer text |
<p>Spending and delivery plans for the Dame Barbara Windsor Dementia Mission are currently
in development. The Dementia Mission Co-Chairs Hilary Evans and Professor Nadeem Sarwar
have, and continue to, engage extensively across the sector to understand and develop
the missions’ key aims, ensuring it addresses the challenges the sector faces and
that patient voices are heard. This has informed the missions focus on three key pillars:
biomarkers and experimental medicine; clinical trials infrastructure and innovation;
and end-to-end implementation.</p><p>In March 2024, the Government hosted a roundtable
and reception where charities, academics, investors, business leaders, and people
with lived experience came together to further accelerate efforts to tackle this devastating
illness, and to thank all those involved in supporting dementia research, including
charities across the United Kingdom. This event made a series announcements, including:
awarding a share of the £6 million of funding to 10 projects through Innovate UK’s
Small Business Research Initiative (SBRI) dementia biomarker tools competition; the
appointment of Scott Mitchell as the People’s Champion for the Dementia Mission; the
appointment of Dr Ruth McKernan CBE as Chair of the Scientific Advisory Board for
the Neurodegeneration Initiative, which will be a public-private partnership delivering
the mission's objectives around biomarkers, boosting the number and speed of clinical
trials in dementia and neurodegeneration, and working with regulatory bodies around
the implementation of new treatments; and the appointment of the Medicines Discovery
Catapult as the delivery partner for the establishment of the Neurodegeneration Initiative.
The Dame Barbara Windsor Dementia Mission continues to develop its deliverables, and
will announce further plans for their delivery in due course.</p>
|
|
